Evotec has partnered Bristol-Myers Squibb to launch a $20m commercialisation programme aimed at academic institutions in Germany’s Rhine-Main-Neckar region.
Evotec, the Germany-based drug discovery company, has added academic institutions from Germany’s Rhine-Main-Neckar region to its therapeutics commercialisation initiative.
Bristol-Myers Squibb is serving as the pharmaceutical partner to the initiative.
BeLab2122 is the latest initiative that forms part of BRIDGE, a programme created by Evotec to support drug discovery and commercialisation at academic institutions across Europe and North America.
Spinouts resulting from the partnership are collectively owned by the involved parties.
BeLab2122 is mediated and supported…
